Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

Cited In for PubMed (Select 20370912)

1.

Associations Between Hyperuricemia and Chronic Kidney Disease: A Review.

Prasad Sah OS, Qing YX.

Nephrourol Mon. 2015 May 23;7(3):e27233. doi: 10.5812/numonthly.7(3)2015.27233. eCollection 2015 May. Review.

2.

Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.

Wen CC, Yee SW, Liang X, Hoffmann TJ, Kvale MN, Banda Y, Jorgenson E, Schaefer C, Risch N, Giacomini KM.

Clin Pharmacol Ther. 2015 May;97(5):518-25. doi: 10.1002/cpt.89. Epub 2015 Apr 6.

3.

Efficacy and safety of febuxostat in elderly female patients.

Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H, Yuzawa Y, Nagamatsu T, Yamada S.

Clin Interv Aging. 2014 Sep 4;9:1489-93. doi: 10.2147/CIA.S70855. eCollection 2014.

4.

Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.

Takai M, Yamauchi T, Fujita K, Lee S, Ookura M, Kishi S, Urasaki Y, Yoshida A, Iwasaki H, Ueda T.

Oncol Lett. 2014 Oct;8(4):1523-1527. Epub 2014 Jul 30.

5.

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.

Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K.

Clin Rheumatol. 2014 Nov;33(11):1643-8. doi: 10.1007/s10067-014-2745-5. Epub 2014 Jul 22.

6.

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.

Sofue T, Inui M, Hara T, Nishijima Y, Moriwaki K, Hayashida Y, Ueda N, Nishiyama A, Kakehi Y, Kohno M.

Drug Des Devel Ther. 2014 Feb 17;8:245-53. doi: 10.2147/DDDT.S56597. eCollection 2014.

7.

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, Makino H, Matsuo S, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H.

Trials. 2014 Jan 16;15:26. doi: 10.1186/1745-6215-15-26.

8.

Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.

Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1960-7. doi: 10.2215/CJN.01760213. Epub 2013 Aug 8.

9.

The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality.

Gustafsson D, Unwin R.

BMC Nephrol. 2013 Jul 29;14:164. doi: 10.1186/1471-2369-14-164. Review.

10.

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.

Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewé RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Müller-Ladner U, Ostergaard M, Zochling J, Falzon L, van der Heijde DM.

Ann Rheum Dis. 2014 Feb;73(2):328-35. doi: 10.1136/annrheumdis-2013-203325. Epub 2013 Jul 18.

11.

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice.

Karve AV, Jagtiani SS, Chitnis KA.

Indian J Pharmacol. 2013 May-Jun;45(3):244-7. doi: 10.4103/0253-7613.111922.

12.

Diabetes and gout: efficacy and safety of febuxostat and allopurinol.

Becker MA, MacDonald PA, Hunt BJ, Jackson RL.

Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12.

13.

Uric acid and chronic kidney disease: which is chasing which?

Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E.

Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029. Epub 2013 Mar 29. Review.

14.

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP.

Arthritis Res Ther. 2013 Feb 1;15(1):R25. doi: 10.1186/ar4159.

15.

Latest evidence on gout management: what the clinician needs to know.

Burns CM, Wortmann RL.

Ther Adv Chronic Dis. 2012 Nov;3(6):271-86. doi: 10.1177/2040622312462056.

16.

Chronic hyperuricemia, uric acid deposit and cardiovascular risk.

Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C.

Curr Pharm Des. 2013;19(13):2432-8. Review.

17.

Febuxostat for treating chronic gout.

Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008653. doi: 10.1002/14651858.CD008653.pub2. Review.

18.

Uric acid as a target of therapy in CKD.

Jalal DI, Chonchol M, Chen W, Targher G.

Am J Kidney Dis. 2013 Jan;61(1):134-46. doi: 10.1053/j.ajkd.2012.07.021. Epub 2012 Oct 9. Review.

19.

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61. doi: 10.1002/acr.21773. No abstract available.

20.

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk